HIV-specific antibody immunity mediated through NK cells and monocytes

Current HIV Research

Volumn 11, Issue 5, 2013, Pages 388-406

  Kramski, Marit ^a   Parsons, Matthew S ^a   Stratov, Ivan ^a   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ADCC; Antibodies; HIV; KIR; Monocytes; NK cells; Vaccines

Indexed keywords

CD16 ANTIGEN; CD32 ANTIGEN; EPITOPE; FC RECEPTOR; FC RECEPTOR IIA; GRANZYME B; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEUTRALIZING ANTIBODY; NON NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; CELL MEDIATED CYTOTOXICITY; CELL PHAGOCYTOSIS; CHROMIUM 51 RELEASE; EPITOPE MAPPING; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOGLOBULIN VARIABLE REGION; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROTEIN POLYMORPHISM; REVIEW; RHESUS MONKEY; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; TROGOCYTOSIS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MONOCYTES;

EID: 84888988696     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X113116660061     Document Type: Review

References (239)

1. Alter G, Moody MA. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 2010; 202 Suppl 2(Supplement 2): S315-22.
2. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15(8): 866-70.
3. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7(1): e1001251.
4. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337(6091): 183-6.
5. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV1 as a case study. Nat Biotechnol 2012; 30(5): 423-33.
6. Zelda Euler HS. Cross-reactive broadly neutralizing antibodies: timing is everything. Frontiers in Immunology. Frontiers Media SA; 2012; 3.
7. Walker LM, Simek MD, Priddy F, et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010; 6(8).
8. Walker LM, Phogat SK, Chan-Hui P-Y, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-9.
9. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477(7365): 466-70.
10. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 2009; 458(7238): 636-40.
11. Klein F, Gaebler C, Mouquet H, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012; 209(8): 1469-79.
12. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266(5187): 1024-7.
13. Saphire EO, Parren PW, Pantophlet R, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001; 293(5532): 1155-9.
14. Wu X, Yang Z-Y, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993): 856-61.
15. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333(6049): 1593-602.
16. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70(2): 1100-8.
17. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67(11): 6642-7.
18. Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1994; 10(12): 1651-8.
19. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491(7424): 406-12.
20. Pancera M, McLellan JS, Wu X, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structurefunction analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010; 84(16): 8098-110.
21. Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012; 12(4): 396-407.
22. van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013; 435(1): 46-56.
23. Tudor D, Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner. AIDS 2011; 25(6): 751-9.
24. Moldt B, Schultz N, Dunlop DC, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J Virol 2011; 85(20): 10572-81.
25. Klein JS, Webster A, Gnanapragasam PNP, Galimidi RP, Bjorkman PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS 2010; 24(11): 1633-40.
26. Gómez-Román VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibodydependent cell-mediated cytotoxicity. J Immunol Methods 2006; 308(1-2): 53-67.
27. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathog 2009; 5(5): e1000433.
28. Parren PWHI, Marx PA, Hessell AJ, et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 SIV HIV at Serum Levels Giving Complete Neutralization In Vitro. J Virol 2001; 75(17): 8340-7.
29. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Pro Nat Acad of Sci USA 2011; 108(27): 11181-6.
30. Moore MD, Cookson J, Coventry VK, et al. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics. J Biol Chem 2011; 286(4): 2526-35.
31. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73(5): 4009-18.
32. Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002; 20(15): 1922-5.
33. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2013.
34. Trkola A, Kuster H, Rusert P, Joos B, Fischer M. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005 11(6): 615-22.
35. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
36. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65.
37. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
38. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71.
39. Wren L, Kent SJ. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccines 2011; 7(4): 466-73.
40. Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001; 75(24): 12161-8.
41. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449(7158): 101-4.
42. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80(12): 6177-81.
43. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4(5): 388-93.
44. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262(1): 5-25.
45. Yu Q, Yu R, Qin X. The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol 2010; 7(5): 334-40.
46. Daëron M. Fc receptor biology. Annu Rev Immunol 1997.
47. Masuda A, Yoshida M, Shiomi H, et al. Role of Fc Receptors as a therapeutic target. Inflamm Allergy Drug Targets 2009; 8(1): 80-6.
48. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8(1): 34-47.
49. Smalls-Mantey AA, Doria-Rose NN, Klein RR, et al. Antibodydependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86(16): 8672-80.
50. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82(11): 5450-9.
51. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294(1-2): 15-22.
52. Madhavi V, Navis M, Chung AW, et al. Activation of NK cells by HIV-specific ADCC antibodies: Role for granulocytes in expressing HIV-1 peptide epitopes. Hum Vaccines Immunother 2013; 9(5): 1011-8.
53. Tiemessen CT, Paximadis M, Minevich G, et al. Natural killer cell responses to HIV-1 peptides are associated with more activating KIR genes and HLA-C genes of the C1 allotype. J Acquir Immune Defic Syndr 2011; 57(3): 181-9.
54. Tiemessen CT, Shalekoff S, Taylor SM, et al. Natural Killer Cells That Respond to Human Immunodeficiency Virus Type 1 (HIV-1) Peptides Are Associated with Control of HIV-1 Infection. J Infect Dis 2010; 202(9): 1444-53.
55. Thobakgale CF, Fadda L, Lane K, et al. Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection. J Virol 2012; 86(12): 6986-93.
56. Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011; 58(2): 127-31.
57. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182(2): 1202-10.
58. Tiemessen CT, Shalekoff S, Meddows-Taylor S, et al. Cutting Edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182(10): 5914-8.
59. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412(1): 110-6.
60. Chung AW, Isitman G, Navis M, et al. Immune escape from HIVspecific antibody-dependent cellular cytotoxicity (ADCC) pressure. Pro Nat Acad Sci USA 2011; 108(18): 7505-10.
61. Wren LH, Chung AW, Isitman G, et al. Specific antibodydependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138(2): 116-23.
62. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J Virol 2005; 79(4): 2042-9.
63. Alter G, Martin MP, Teigen N, et al. Differential natural killer cellmediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Experiment Med 2007; 204(12): 3027-36.
64. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178(10): 6596-603.
65. Haynes BFB, Gilbert PBP, McElrath MJM, et al. Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86.
66. Alpert MD, Heyer LN, Williams DEJ, et al. A novel assay for ADCC against HIV-1 or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 2012; 86(22): 12039-52.
67. Pollara JJ, Hart LL, Brewer FF, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 2011; 79(8): 603-12.
68. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157(5): 2168-73.
69. Nag P, Kim J, Sapiega V, et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004; 190(11): 1970-8.
70. Cox JH, Garner RP, Redfield RR, et al. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. AIDS Res Hum Retroviruses 1999; 15(9): 847-54.
71. Cox JH. HIV-1-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC). Methods Mol Med 1999; 17: 373-81.
72. Yamada T, Watanabe N, Nakamura T, Iwamoto A. Antibodydependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J Immunol 2004; 172(4): 2401-6.
73. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J Infect Dis 2002; 185(4): 439-47.
74. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cellmediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX^(R) B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23(19): 2522-9.
75. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249(1-2): 99-110.
76. Gómez-Román VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174(4): 2185-9.
77. Vaine M, Wang S, Liu Q, et al. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS ONE 2010; 5(11): e13916.
78. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89. 6P challenge in rhesus macaques. J Virol 2010; 84(14): 7161-73.
79. Patterson LJ, Daltabuit-Test M, Xiao P, et al. Rapid SIV Envspecific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 2011; 411(1): 87-102.
80. Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R. A novel EGFP-CEMNKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J Immunol Methods 2006; 315(1-2): 1-10.
81. Kramski M, Schorcht A, Johnston APR, et al. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Immunol Methods 2012; 384(12): 51-61.
82. Baum LL. Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010; 7(1): 11-8.
83. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23(8): 897-906.
84. Lyerly HK, Reed DL, Matthews TJ, et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3(4): 409-22.
85. Berger CT, Alter G. Natural killer cells in spontaneous control of HIV infection. Curr Opin HIV AIDS 2011; 6(3): 208-13.
86. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001 Aug; 75(15): 6953-61.
87. Johansson SE, Rollman E, Chung AW, et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 2011; 24(5): 359-68.
88. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996; 10(2): 258-66.
89. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 21(3): 227-33.
90. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265(1): 29-42.
91. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012; 8(8): e1002890.
92. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012; 8(6): e1002739.
93. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: Paradigm for protection or targets for ambush. Nat Rev Immunol 2005; 5(11): 835-43.
94. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005 Feb 22; 102(8): 2886-91.
95. Tarazona R, Casado JG, Delarosa O, et al. Selective depletion of CD56 dim NK cell subsets and maintenance of CD56 bright NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002; 22(3): 176-83.
96. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-74.
97. Lichtfuss GF, Cheng W-J, Farsakoglu Y, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol 2012; 189(3): 1491-9.
98. Kutteh WH, Prince SJ, Hammond KR, Kutteh CC, Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996; 104(3): 538-42.
99. Russell MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002; 4(6): 667-77.
100. Mestecky J, Moldoveanu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 2005; 53(5): 208-14.
101. Buchacz K, Parekh BS, Padian NS, et al. HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retroviruses 2001; 17(18): 1689-93.
102. Miyazawa M, Lopalco L, Mazzotta F, et al. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 2009; 23(2): 161-75.
103. Lai SK, Hida K, Shukair S, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009; 83(21): 11196-200.
104. Hope TJ. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med 2011; 17(10): 1195-7.
105. Papagno L, Alter G, Assoumou L, et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011; 25(1): 27-36.
106. Cohen J. AIDS research. Novel antibody response may explain HIV vaccine success. Science 2011; 333(6049): 1560.
107. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490(7420): 417-20.
108. Bonsignori M, Montefiori DC, Wu X, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012; 86(8): 4688-92.
109. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Pro Nat Acad Sci 2013; 110(22): 9019-24.
110. Mathew GDG, Qualtiere LFL, Neel HBH, Pearson GRG. IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 1981 14; 27(2): 175-80.
111. Griffiss JMJ, Goroff DKD. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol 1983; 130(6): 2882-5.
112. Jarvis GA, Griffiss JM. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol 1991; 147(6): 1962-7.
113. Karasavvas NN, Billings EE, Rao MM, et al. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Res Hum Retroviruses. 2012; 28(11): 1444-57.
114. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86(21): 11521-32.
115. Liao H-X, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013; 38(1): 176-86.
116. Sun Y, Asmal M, Lane S, et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol. 2011 Jul; 85(14): 6906-12.
117. Asmal M, Sun Y, Lane S, et al. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J Virol 2011; 85(11): 5465-75.
118. Banks ND, Kinsey N, Clements J, Hildreth JEK. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIVinfected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18(16): 1197-205.
119. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009; 83(2): 791-801.
120. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009; 182(6): 3718-27.
121. Brocca-Cofano E, McKinnon K, Demberg T, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011; 29(17): 3310-9.
122. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012; 86(8): 4644-57.
123. Bomsel M, Tudor D, Drillet A-S, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34(2): 269-80.
124. Bialuk I, Whitney S, Andresen V, et al. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 2011; 30(1): 78-94.
125. Ohkawa SS, Xu KK, Wilson LAL, Montelaro RR, Martin LNL, Murphey-Corb MM. Analysis of envelope glycoprotein-specific antibodies from SIV-infected and gp110-immunized monkeys in ACC and ADCC assays. AIDS Res Hum Retroviruses 1995; 11(3): 395-403.
126. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482(7383): 89-93.
127. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354(6353): 453-9.
128. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA. 2003 Apr 1; 100(7): 4144-9.
129. Moore PLP, Gray ESE, Wibmer CKC, Bhiman JNJ, Nonyane MM, Sheward DJD, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Oct 31; 18(11): 1688-92.
130. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS; 5(9): e1000594.
131. Bar KJ, Tsao C-Y, Iyer SS, et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog 2012; 8(5): e1002721.
132. Burwitz BJ, Giraldo-Vela JP, Reed J, et al. CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller. Retrovirology 2012; 9: 91.
133. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5(3): 233-6.
134. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibodymediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420(6916): 678-82.
135. Mascola JR, Montefiori DC. HIV-1: nature's master of disguise. Nat Med. 2003; 9(4): 393-4.
136. Peut V, Campbell S, Gaeguta A, et al. Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol 2009; 83(17): 8986-92.
137. Peut V, Kent SJ. Fitness constraints on immune escape from HIV: Implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res 2006; 4(2): 191-7.
138. Peut V, Kent SJ. Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology 2009; 384(1): 21-7.
139. Arts EJ, Quiñones-Mateu ME. Sorting out the complexities of HIV-1 fitness. AIDS 2003; 17(5): 780-1.
140. Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 2011; 24(2): 171-5.
141. Tarek N, Le Luduec J-B, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 2012; 122(9): 3260-70.
142. Parsons MS, Wren L, Isitman G, et al. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibodydependent cellular cytotoxicity. J Virol 2012; 86(8): 4488-95.
143. Parsons MS, Zipperlen K, Gallant M, Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16mediated effector functions of natural killer cells. J Leukoc Biol 2010; 88(5): 905-12.
144. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006; 25(2): 331-42.
145. Ward JP, Bonaparte MI, Barker E. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 2004; 18(13): 1769-79.
146. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110(7): 2561-4.
147. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21(21): 3940-7.
148. Wren L, Parsons MS, Isitman G, et al. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS ONE 2012; 7(6): e38580.
149. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo. Curr Opin Organ Transpl 2011; 16(1): 7-14.
150. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436(7051): 709-13.
151. Kim S, Sunwoo JB, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Nat Acad Sci 2008; 105(8): 3053-8.
152. Höglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 2010; 10(10): 724-34.
153. Fauriat C, Ivarsson MA, Ljunggren H-G, Malmberg K-J, Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115(6): 1166-74.
154. Brodin P, Kärre K, Höglund P. NK cell education: not an on-off switch but a tunable rheostat. Trend Immunol 2009; 30(4): 143-9.
155. Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 2009; 182(8): 4572-80.
156. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39(6): 733-40.
157. López-Vázquez A, Miña-Blanco A, Martínez-Borra J, et al. Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population. Hum Immunol 2005; 66(3): 285-9.
158. Boulet S, Kleyman M, Kim JY, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22(12): 1487-91.
159. Boulet S, Song R, Kamya P, et al. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 2010; 184(4): 2057-64.
160. Jost S, Altfeld M. Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect 2012; 14(11): 904-15.
161. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10(6): 661-71.
162. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998; 391(6665): 397-401.
163. Nattermann J, Nischalke HD, Hofmeister V, et al. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 2005; 10(1): 95-107.
164. Martini F, Agrati C, D'Offizi G, Poccia F. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. Int J Immunopathol Pharmacol 2005; 18(2): 269-76.
165. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998; 391(6669): 795-9.
166. Bonaparte MI, Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 2004; 104(7): 2087-94.
167. Shah AH, Sowrirajan B, Davis ZB, et al. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by down-modulation of NTB-A by Vpu. Cell Host Microbe 2010; 8(5): 397-409.
168. Fausther-Bovendo H, Sol-Foulon N, Candotti D, et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS. 2009; 23(9): 1077-87.
169. Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107(1): 159-66.
170. Forthal DN, Gabriel EE, Wang A. Association of Fcγ receptor IIIa (FcγRIIIa) genotype with the rate of HIV infection following gp120 vaccination. Blood 2012; 120(14): 2836-42.
171. Kijak G, Sue Li, Paris R, et al. Modulation of vaccine effect by Fcgamma receptor 3a genetic polymorphism in RV144. 19th Conference on Retroviruses and Opportunistic Infections. Seattle; 2012.
172. Hwang I, Zhang T, Scott JM, et al. Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol 2012; 24(12): 793-802.
173. Nguyen QH, Roberts RL, Ank BJ, Lin SJ, Lau CK, Stiehm ER. Enhancement of antibody-dependent cellular cytotoxicity of neonatal cells by interleukin-2 (IL-2) and IL-12. Clin Diagn Lab Immunol 1998; 5(1): 98-104.
174. Nguyen QH, Roberts RL, Ank BJ, Lin SJ, Thomas EK, Stiehm ER. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells. Cell Immunol 1998; 185(2): 83-92.
175. Lin SJ, Roberts RL, Ank BJ, Nguyen QH, Thomas EK, Stiehm ER. Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. J Clin Immunol 1998; 18(5): 335-45.
176. Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16mediated IFN-gamma production and antibodydependent cellular cytotoxicity in human NK cells. J Immunol 2008; 181(6): 3784-92.
177. Huenecke S, Zimmermann SY, Kloess S, et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16-subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 2010; 33(2): 200-10.
178. Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL. Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol 2004; 11(5): 879-88.
179. DeBlaker-Hohe DF, Yamauchi A, Yu CR, Horvath-Arcidiacono JA, Bloom ET. IL-12 synergizes with IL-2 to induce lymphokineactivated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 1995; 165(1): 33-43.
180. Juelke K, Killig M, Thiel A, Dong J, Romagnani C. Education of hyporesponsive NK cells by cytokines. Eur J Immunol 2009; 39(9): 2548-55.
181. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys 2012; 526(2): 159-66.
182. Zauner G, Selman MHJ, Bondt A, et al. Glycoproteomic analysis of antibodies. Mol. Cell Proteomics 2013; 11(5): 879-88.
183. Böhm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012; 34(3): 443-53.
184. Moore JS, Wu X, Kulhavy R, et al. Increased levels of galactosedeficient IgG in sera of HIV-1-infected individuals. AIDS 2005; 19(4): 381-9.
185. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012; 1253(1): 170-80.
186. Ferrara C, Grau S, Jäger C, et al. Unique carbohydratecarbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Pro Nat Acad Sci 2011; 108(31): 12669-74.
187. Hristodorov D, Fischer R, Linden L. With or Without Sugar? (A)glycosylation of Therapeutic Antibodies. Mol Biotechnol 2012; 110(7): 2561-4.
188. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8(3): 226-34.
189. Forthal DN, Gach JS, Landucci G, et al. Fc-Glycosylation Influences Fc{gamma} Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. The Journal of Immunology 2010; 185(11): 6876-82.
190. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86(11): 6189-96.
191. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181(11): 8120-32.
192. Iida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 2006; 12(9): 2879-87.
193. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol 2003; 26(2): 247-63.
194. Collini P, Noursadeghi M, Sabroe I, Miller RF, Dockrell DH. Monocyte and macrophage dysfunction as a cause of HIV-1 induced dysfunction of innate immunity. Curr Mol Med 2010; 10(8): 727-40.
195. Dugast A-S, Tonelli A, Berger CT, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011 5; 415(2): 160-7.
196. Ackerman ME, Moldt B, Wyatt RT, et al. A robust, highthroughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 2011; 366(1-2): 8-19.
197. McAndrew EG, Dugast A-S, Licht AF, Eusebio JR, Alter G, Ackerman ME. Determining the Phagocytic Activity of Clinical Antibody Samples. J Vis Exp 2011; (57): e3588-8.
198. Liu Q, Sun Y, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83(17): 8705-12.
199. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113(16): 3716-25.
200. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179(11): 7916-23.
201. French MA, Tanaskovic S, Law MG, et al. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" FcgammaRIIa genotype. AIDS 2010; 24(13): 1983-90.
202. Ackerman ME, Dugast A-S, McAndrew EG, et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b. J Virol 2013; 87(10): 5468-76.
203. Kramski M, Center RJ, Wheatley AK, et al. Hyperimmune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies with Broad Neutralizing Activity for HIV-1 Envelope with Potential Use in Microbicides. Antimicrob Agent Chemother 2012; 56(8): 4310-9.
204. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med 2011; 15(7): 1458-73.
205. Arnold PY, Davidian DK, Mannie MD. Antigen presentation by T cells: T cell receptor ligation promotes antigen acquisition from professional antigen-presenting cells. Eur J Immunol 1997; 27(12): 3198-205.
206. Puaux A-L, Campanaud J, Salles A, et al. A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry. Eur J Immunol 2006; 36(3): 779-88.
207. Hudrisier D, Bongrand P. Intercellular transfer of antigenpresenting cell determinants onto T cells: molecular mechanisms and biological significance. FASEB J 2002; 16(6): 477-86.
208. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature 2001; 411(6836): 489-94.
209. McCann FE, Eissmann P, Onfelt B, Leung R, Davis DM. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol 2007; 178(6): 3418-26.
210. Carlin LM, Eleme K, McCann FE, Davis DM. Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. J Exp Med 2001; 194(10): 1507-17.
211. Tabiasco J, Espinosa E, Hudrisier D, Joly E, Fournié J-J, Vercellone A. Active trans-synaptic capture of membrane fragments by natural killer cells. Eur J Immunol 2002; 32(5): 1502-8.
212. Herrera OB, Golshayan D, Tibbott R, Salcido Ochoa F, James MJ, Marelli-Berg FM, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol. 2004 Oct 15; 173(8): 4828-37.
213. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A novel pathway of antigen presentation by dendritic and endothelial cells: Implications for allorecognition and infectious diseases. Transplantation 2006; 82(1 Suppl): S15-8.
214. Xu H, Dhanireddy KK, Kirk AD. Human monocytes as intermediaries between allogeneic endothelial cells and allospecific T cells: a role for direct scavenger receptor-mediated endothelial membrane uptake in the initiation of alloimmunity. J Immunol 2006; 176(2): 750-61.
215. Iwasaki S, Masuda S, Baba T, et al. Plasma-dependent, antibodyand Fcγ receptor-mediated translocation of CD8 molecules from T cells to monocytes. Cytometry A 2011; 79(1): 46-56.
216. Harvey BP, Quan TE, Rudenga BJ, Roman RM, Craft J, Mamula MJ. Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors. J Immunol 2008; 181(6): 4043-51.
217. Pham T, Mero P, Booth JW. Dynamics of macrophage trogocytosis of rituximab-coated B cells. PLoS ONE 2011; 6(1): e14498.
218. Masuda S, Iwasaki S, Tomaru U, et al. Mechanism of Fcγ receptormediated trogocytosis-based false-positive results in flow cytometry. PLoS ONE 2012; 7(12): e52918.
219. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D. The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol 2010; 184(4): 1897-908.
220. Alegre E, HoWangYin K-Y, Favier B, et al. Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res 2010; 20(11): 1239-51.
221. Dopfer EP, Minguet S, Schamel WWA. A new vampire saga: the molecular mechanism of T cell trogocytosis. Immunity 2011; 35(2): 151-3.
222. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003; 4(9): 815.
223. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176(4): 2600-9.
224. Boross P, Jansen JHM, Pastula A, van der Poel CE, Leusen JHW. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol Lett 2012; 143(1): 44-52.
225. Horner H, Frank C, Dechant C, et al. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocytemediated cytotoxicity. J Immunol 2007; 179(1): 337-45.
226. Ackerman ME, Dugast A-S, Alter G. Emerging Concepts on the Role of Innate Immunity in the Prevention and Control of HIV Infection. Annu Rev Med 2012; 63(1): 113-30.
227. Kimberly RP, Wu J, Gibson AW, et al. Diversity and duplicity: human FCgamma receptors in host defense and autoimmunity. Immunol Res 2002; 26(1-3): 177-89.
228. Takai TT. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2(8): 580-92.
229. Fossati G, Bucknall RC, Edwards SW. Fcgamma receptors in autoimmune diseases. Eur J Clin Invest 2001; 31(9): 821-31.
230. Monteiro RC, van de Winkel J. IgA Fc receptors. Annu Rev Immunol 2003.
231. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013; 34(4): 182-91.
232. Williams AP, Bateman AR, Khakoo SI. Hanging in the balance. KIR and their role in disease. Mol Interv 2005; 5(4): 226-40.
233. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009; 83(13): 6798-805.
234. Wong AHW, Williams K, Reddy S, et al. Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults. AIDS Res Hum Retroviruses 2010; 26(4): 459-69.
235. Brunetta E, Fogli M, Varchetta S, et al. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 2010; 24(1): 27-34.
236. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003; 100(25): 15011-6.
237. Jiang Y, He L, Chen H, et al. Alteration of inhibitory and activating NK cell receptor expression on NK cells in HIV-infected Chinese. Cell Immunol 2011; 271(2): 219-26.
238. Zhang R, Xu J, Hong K, et al. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status. AIDS 2007; 21 Suppl 8: S9-17.
239. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 2007; 179(9): 5977-89.